Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, Gross ME, Shi Y, Webb IJ, Agus DB. Dreicer R, et al. Among authors: macvicar gr. Clin Cancer Res. 2014 Mar 1;20(5):1335-44. doi: 10.1158/1078-0432.CCR-13-2436. Epub 2014 Jan 13. Clin Cancer Res. 2014. PMID: 24418642 Clinical Trial.
Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216).
Goldkorn A, Tangen C, Plets M, Morrison GJ, Cunha A, Xu T, Pinski JK, Ingles SA, Triche T, Harzstark AL, Kohli M, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN Jr, Hussain MHA, Quinn DI, Vogelzang NJ, Thompson IM Jr, Agarwal N. Goldkorn A, et al. Among authors: macvicar gr. Clin Cancer Res. 2021 Apr 1;27(7):1967-1973. doi: 10.1158/1078-0432.CCR-20-3587. Epub 2021 Jan 26. Clin Cancer Res. 2021. PMID: 33500355 Free PMC article. Clinical Trial.
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695).
Flaig TW, Tangen CM, Daneshmand S, Alva A, Lerner SP, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM Jr. Flaig TW, et al. Among authors: macvicar gr. Clin Cancer Res. 2021 May 1;27(9):2435-2441. doi: 10.1158/1078-0432.CCR-20-2409. Epub 2021 Feb 10. Clin Cancer Res. 2021. PMID: 33568346 Free PMC article. Clinical Trial.
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski JK, Ingles S, Triche TJ, MacVicar GR, Vaena DA, Crispino AW, McConkey DJ, Lara PN Jr, Hussain MHA, Quinn DI, Dorff TB, Lerner SP, Thompson I Jr, Agarwal N. Goldkorn A, et al. Among authors: macvicar gr. JAMA Netw Open. 2024 Oct 1;7(10):e2437871. doi: 10.1001/jamanetworkopen.2024.37871. JAMA Netw Open. 2024. PMID: 39374015 Free PMC article. Clinical Trial.
Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D; Southwest Oncology Group Trial 9346 (INT-0162). Hussain M, et al. J Clin Oncol. 2006 Aug 20;24(24):3984-90. doi: 10.1200/JCO.2006.06.4246. J Clin Oncol. 2006. PMID: 16921051
Prostate cancer, version 1.2014.
Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M; National comprehensive cancer network. Mohler JL, et al. Among authors: macvicar gr. J Natl Compr Canc Netw. 2013 Dec 1;11(12):1471-9. doi: 10.6004/jnccn.2013.0174. J Natl Compr Canc Netw. 2013. PMID: 24335682
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.
Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radtke AO, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Al-Hawary M, Smith DC. Hussain M, et al. Among authors: macvicar gr. Cancer. 2014 Sep 1;120(17):2684-93. doi: 10.1002/cncr.28767. Epub 2014 May 6. Cancer. 2014. PMID: 24802654 Free PMC article. Clinical Trial.
26 results